All Stories

  1. Journey of therapeutic antibodies: from discovery to future
  2. Lignin-based biopharmaceuticals from nature to medicine: current trends, future prospects and emerging challenges
  3. Radioligand–Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis
  4. Photosensitizer-Antibody Conjugates (PhotoBodies): Emerging Frontiers in the Field of Theranostics
  5. Polybodies for the treatment of respiratory syncytial virus infection
  6. Chemotherapeutic Drug—Antibody Conjugates (ChemoBodies): Recent Advances and Future Directions
  7. Challenges and advances in the development of antidotes against A-series nerve agents
  8. Efficacy and safety of transcutaneous electrical nerve stimulation versus oxybutynin in the treatment of overactive bladder in children: a systematic review and meta-analysis
  9. Cardioprotective Potential of ApoE-Derived Peptide (ApoEFrag) in Myocardial Infarction in Rats: A Mechanistic Study
  10. Amino acid deprivation vs. mainstream cancer therapeutics: exploring the potential and limitations
  11. Human Paraoxonase 1: From Bloodstream Enzyme to Disease Fighter & Therapeutic Intervention
  12. Neuroprotective potential of ApoE-mimetic peptide (ApoEFrag) in stroke models: Neurobehavioural and mechanistic study
  13. Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α
  14. Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide Therapy
  15. What are biopharmaceuticals?
  16. ApoE potential in CNS drugs targeting and as CNS therapeutic
  17. Antigen Specificity: A Fluctuating Aspect in the Development of Clinical Antibodies?
  18. Endostatin in disease modulation: From cancer to beyond
  19. Role of paraoxonase 1 in organophosphate G-series nerve agent poisoning and future therapeutic strategies
  20. Polybodies: Next-generation clinical antibodies
  21. Broad-spectrum anti-cancer activity of fused human arginase variants
  22. Warfare Nerve Agents and Paraoxonase-1 as a Potential Prophylactic Therapy against Intoxication
  23. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies
  24. Treating liver cancer through arginine depletion
  25. Polyvalency: an emerging trend in the development of clinical antibodies
  26. Towards development of biobetter: L-asparaginase a case study
  27. Catalysing and Accelerating a New Phase in Indian Biopharma
  28. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics
  29. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status
  30. Development and characterization of fused human arginase I for cancer therapy
  31. Human arginase I: a potential broad-spectrum anti-cancer agent
  32. Fused human paraoxonase 1 as a prophylactic agent against organophosphate poisoning
  33. Polyspecificity - An emerging trend in the development of clinical antibodies
  34. Paraoxonase 1 as a potential prophylactic against nerve agent poisoning
  35. Types of Wound Dressings and Materials used in Mild to Moderately Exuding Wounds: A Review
  36. Apolipoprotein-mimetic Peptides: Current and Future Prospectives
  37. Immunomodulatory potential of apolipoproteins and their mimetic peptides in asthma: Current perspective
  38. Human arginase 1, a Jack of all trades?
  39. Therapeutic potential of ApoE-mimetic peptides in CNS disorders: Current perspective
  40. HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?
  41. Optimization of medium composition to increase the expression of recombinant human interferon-β using the Plackett–Burman and central composite design in E. coli SE1
  42. Human Arginase I (Arg I)—A Potential Broad-spectrum Anti-cancer Agent: Perspectives and the Road Ahead
  43. APOE-Derived Peptides Attenuated Diabetes-Induced Oxidative Stress and Inflammation
  44. Is Human Paraoxonase 1 the Saviour Against the Persistent Threat of Organophosphorus Nerve Agents?
  45. Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics
  46. Antibiotic-free expression system for the production of human interferon-beta protein
  47. Towards Understanding the Catalytic Mechanism of Human Paraoxonase 1: Experimental and In Silico Mutagenesis Studies
  48. Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead
  49. Refolded Recombinant Human Paraoxonase 1 Variant Exhibits Prophylactic Activity Against Organophosphate Poisoning
  50. Toward Understanding the Catalytic Mechanism of Human Paraoxonase 1: Site-Specific Mutagenesis at Position 192
  51. Abstract 12419: Preclinical Safety and Efficacy of a Novel Thrombolytic Agent Administered by Rapid Bolus Injection: Clot Specific Streptokinase (CSSK/SMRX-11)
  52. Improving Properties of Recombinant SsoPox by Site-Specific Pegylation
  53. Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of Escherichia coli
  54. Expression, purification and immobilization of recombinant AiiA enzyme onto magnetic nanoparticles
  55. Improving storage stability of recombinant organophosphorus hydrolase
  56. Interplay between amino acid residues at positions 192 and 115 in modulating hydrolytic activities of human paraoxonase 1
  57. Properties of apolipoprotein E derived peptide modulate their lipid-binding capacity and influence their anti-inflammatory function
  58. Stabilization Studies on Bacterially Produced Human Paraoxonase 1 for Improving Its Shelf Life
  59. Human Paraoxonase 1 as a Pharmacologic Agent: Limitations and Perspectives
  60. Apolipoprotein E Derived Peptides Inhibit the Pro-Inflammatory Effect of Lysophosphatidylcholine
  61. Oxidized-phospholipids in reconstituted high density lipoprotein particles affect structure and function of recombinant paraoxonase 1
  62. Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme
  63. Differential interaction of peptides derived from C-terminal domain of human apolipoprotein E with platelet activating factor analogs
  64. The Chemical Nature of the Polar Functional Group of Oxidized Acyl Chain Uniquely Modifies the Physicochemical Properties of Oxidized Phospholipid-Containing Lipid Particles
  65. Physicochemical properties of bacterial pro-inflammatory lipids influence their interaction with apolipoprotein-derived peptides
  66. Oxidized phospholipid content destabilizes the structure of reconstituted high density lipoprotein particles and changes their function
  67. Characterization of Oxidized Phospholipid containing Reconstituted High Density Lipoprotein Particle
  68. A Therapeutic Chemical Chaperone Inhibits Cholera Intoxication and Unfolding/Translocation of the Cholera Toxin A1 Subunit
  69. Closely related oxidized phospholipids differentially modulate the physicochemical properties of lipid particles
  70. Membrane lipid composition differentially modulates the function of human plasma platelet activating factor-acetylhydrolase
  71. Contribution of Subdomain Structure to the Thermal Stability of the Cholera Toxin A1 Subunit
  72. Oxidatively modified fatty acyl chain determines physicochemical properties of aggregates of oxidized phospholipids
  73. Stabilization of the Tertiary Structure of the Cholera Toxin A1 Subunit Inhibits Toxin Dislocation and Cellular Intoxication
  74. Peptide derived from the lipid binding domain of Group IB human pancreatic phospholipase A2 possesses antibacterial activity
  75. Membrane surface charge modulates lipoprotein complex forming capability of peptides derived from the C-terminal domain of apolipoprotein E
  76. Preferential binding of apolipoprotein E derived peptides with oxidized phospholipid
  77. Bax C-Terminal Peptide - Insights Into Membrane Interactions
  78. Conformational Instability of the Cholera Toxin A1 Polypeptide
  79. The Pertussis Toxin S1 Subunit Is a Thermally Unstable Protein Susceptible to Degradation by the 20S Proteasome
  80. Isoform-Specific Membrane Insertion of Secretory Phospholipase A2 and Functional Implications
  81. Structural and Functional Effects of Tryptophans Inserted into the Membrane-binding and Substrate-binding Sites of Human Group IIA Phospholipase A2
  82. Carbohydrate-induced modulation of cell membrane. VIII. Agglutination with mammalian lectin galectin-1 increases osmofragility and membrane fluidity of trypsinized erythrocytes
  83. Evidence for the Regulatory Role of the N-terminal Helix of Secretory Phospholipase A2 from Studies on Native and Chimeric Proteins
  84. Positioning Membrane Proteins by Novel Protein Engineering and Biophysical Approaches
  85. Membrane Fluidity Is a Key Modulator of Membrane Binding, Insertion, and Activity of 5-Lipoxygenase
  86. Modulation of Human 5-Lipoxygenase Activity by Membrane Lipids, by
  87. The N-terminal α-Helix of Pancreatic Phospholipase A2 Determines Productive-mode Orientation of the Enzyme at the Membrane Surface
  88. Modulation of Human 5-Lipoxygenase Activity by Membrane Lipids
  89. Oxidation of Goat Hepatic Galectin-1 Induces Change in Secondary Structure
  90. Involvement of a Nine-residue Loop of Streptokinase in the Generation of Macromolecular Substrate Specificity by the Activator Complex through Interaction with Substrate Kringle Domains
  91. Studies on a Doubleheaded Protease Inhibitor from Phaseolus mungo
  92. Carbohydrate induced modulation of cell membrane VII. Binding of exogenous lectin increases osmofragility of erythrocytes
  93. Carbohydrate induced modulation of cell membrane. VI. Binding of exogenous lectin induces susceptibility of erythrocytes to free radical damage: a spin label study